The MarketWatch News Department was not involved in the creation of this content. Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology GERMANTOWN, MARYLAND / ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, the leading provider of innovative induced pluripotent stem cells (iPSC), announces the issuance of the groundbreaking induced Allogeneic Cell Tolerance (iACT ...

Researchers from Monash University in Melbourne and The University of Western Australia have demonstrated how a reprogramming method imitates embryonic epigenetic reset. Transient naive treatment (TNT ...

The "Technological Advances in Regenerative Medicine" report has been added to ResearchAndMarkets.com's offering. This report covers incremental technological improvements and the new platforms that ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.

Method to improve the cell expansion step during joint regenerative therapies (like MACI therapy) to restore knee or other joint injuries in young, healthy patients, often athletes. An improved method ...